Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camilla Portinari

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|May 3, 2026
Bempedoic acid and increased serum uric acid levels: a matter of concern?Luca Bonanni, Marta Biolo, Giorgia Marodin, et al.
Frontiers in Cardiovascular Medicine|May 18, 2026
Pathogenic interplay between markedly elevated plasma lipoprotein(a) levels and prothrombotic mechanisms: a case reportMarta Biolo, Angela Napolitano, Luca Spiezia, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 8, 2026
Focus on lipoprotein(a)Marta Biolo, Camilla Portinari, Camilla Goffi, et al.
Current Atherosclerosis Reports|July 18, 2025
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?Marta Biolo, Federica Galimberti, Camilla Portinari, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nutrition, Metabolism, and Cardiovascular Diseases : NMCD|May 3, 2026
Bempedoic acid and increased serum uric acid levels: a matter of concern?Luca Bonanni, Marta Biolo, Giorgia Marodin, et al.
Frontiers in Cardiovascular Medicine|May 18, 2026
Pathogenic interplay between markedly elevated plasma lipoprotein(a) levels and prothrombotic mechanisms: a case reportMarta Biolo, Angela Napolitano, Luca Spiezia, et al.
European Heart Journal Supplements : Journal of the European Society of Cardiology|May 8, 2026
Focus on lipoprotein(a)Marta Biolo, Camilla Portinari, Camilla Goffi, et al.
Current Atherosclerosis Reports|July 18, 2025
ApoC-III as Therapeutic Target: Is it Primetime for Clinical Use?Marta Biolo, Federica Galimberti, Camilla Portinari, et al.
Pageof 1